Read this article first published on The MSL Journal to uncover tips that will help you maintain and even strengthen your relationships with KOLs with engaging virtual meetings.
Medical Science Liaisons have been especially impacted by COVID-19 restrictions on in-person meetings. Most have shifted to connecting with KOLs virtually using videoconferencing solutions like Zoom, Microsoft Teams, or Google Meet. Though definitely a change in the day-to-day life of any MSL, this transition has been relatively smooth.
A survey of 245 KOLs by the Medical Science Liaison Society (MSLS) found that:
Another survey of MSLs which we partnered with MSLS to conduct showed that:
This is encouraging news as virtual meetings are definitely a part of the future of KOL engagement. Whatever the post-COVID landscape looks like, MSLs will likely adopt a hybrid model–mixing in-person and virtual meetings for greater convenience and productivity.
We say this is encouraging because we believe this shift can strengthen the connection between MSLs and KOLs. As a global, remote-first team, we’ve learned firsthand how to make the most of video as a platform for getting business done and building real connections. With lots of practice, our team has discovered ways to make our time on video (and increasingly now in virtual reality) both meaningful and effective.
Here are 10 tips from our experience in the video meeting world. These best practices can help strengthen your virtual meeting skills and maximize the efficiency of your meetings with KOLs.
Continue reading at The MSL Journal here.
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm
Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy
Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network